Enterococcus faecium
Enterococci have developed a variety of mechanisms of resistance to several antibiotics like aminoglycosides, B-lactams, tetracyclines, quinolones, and vancomycin (glycopeptide).
The World Health Organization (WHO) has identified 12 families of bacteria that are most in need of new antibiotic treatments. They are divided into three categories: critical, high and moderate. These 12 bacteria are prioritized based on the level of resistance already present in each. The issue is critical as antibiotic-resistant superbugs become more common.
Critical pathogens are those that cause serious infections and high mortality rates. Three bacteria are listed as critical: Acinetobacter Baumannii, Pseudomonas Aeruginosa, and Enterobacterales.
Learn about their antibiotic resistance and infections
Enterococci have developed a variety of mechanisms of resistance to several antibiotics like aminoglycosides, B-lactams, tetracyclines, quinolones, and vancomycin (glycopeptide).
S. aureus strains are resistant to the isoxazoyl penicillins such as methicillin, oxacillin and flucloxacillin and resistant to vancomycin-intermediate.
Helicobacter pylori infections have been treated using the macrolide antibiotic, clarithromycin. Clarithromycin resistance is increasing worldwide and is the most common cause of H. pylori treatment failure.
Campylobacter remain a leading cause of bacterial gastroenteritis worldwide. Fluoroquinolones are among the most common treatments. Selection pressure in the presence of fluoroquinolones rapidly leads to resistance in Campylobacter.
Salmonella is co-resistance to the first-line antibiotics ampicillin, chloramphenicol and trimethoprim/sulfamethoxazole. Resistance of Salmonella to fluoroquinolone has been increasingly reported after the introduction of fluoroquinolone drug therapy.
Antibiotic resistance in Neisseria gonorrhoeae is rapidly increasing. Extensively resistant Neisseria gonorrhoeae is resistant to both penicillins, sulfonamides, tetracyclines, fluoroquinolones, and macrolides.
These bacteria, classified as high priority, may cause significant infections in other healthy populations. These six bacterial families are a high threat to our health care. This is because their antibiotic resistance is growing, and we have nearly exhausted our treatment options.
Research on antibiotic resistance is important, and it is one of the biggest threats to modern health. Therefore, the development of new treatments for superbugs will be a long-term endeavor. We urgently need new antibiotics to be developed in a timely manner.
Contact UsWe are a preclinical CRO that specializes in the research and development of new treatments for superbugs. Don't put us at risk for superbug infections and difficult treatments - feel free to contact us for research help. We will help and make sure your research project goes smoothly.